2-amino-N-ethyl-acetamide | 62029-79-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-amino-N-ethyl-acetamide
• 英文别名: glycine ethylamide；2-amino-N-ethylacetamide
• CAS: 62029-79-2
• 化学式: C₄H₁₀N₂O
• mdl: MFCD06655350
• 分子量: 102.136
• InChiKey: QCQZFSUBYDWVBG-UHFFFAOYSA-N

物化性质

• 熔点：
  17-19 °C (decomp)
• 沸点：
  136-138 °C(Press: 12 Torr)
• 密度：
  0.980±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924199090

SDS

2-amino-N-ethylAcetamideMSDS英文版

反应信息

• 作为反应物：
  描述：

  2-amino-N-ethyl-acetamide 、 丙酮醛 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 1-ethyl-5-methylpyrazin-2(1H)-one
  参考文献：
  名称：

  10-Hydroxy-7,8-dihydropyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: Potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants

  摘要：

  A series of 10-hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[ 2,3-d]pyridazine-1,9(2H,6H)-diones was synthesized and tested for their inhibition of HIV-1 replication in cell culture. Structure-activity studies indicated that high antiviral potency against wild-type virus as well as viruses containing integrase mutations that confer resistance to three different structural classes of integrase inhibitors could be achieved by incorporation of small aliphatic groups at certain positions on the core template. An optimal compound from this study, 16, inhibits integrase strand-transfer activity with an IC50 value of <= 10 nM, inhibits HIV-1 replication in cell culture with an IC95 value of 35 nM in the presence of 50% normal human serum, and displays modest pharmacokinetic properties in rats (iv t(1/2) = 5.3 h, F = 17%). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.037
• 作为产物：
  描述：

  benzyl N-[2-(ethylamino)-2-oxoethyl]carbamate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 144.0h， 以64.4 g的产率得到2-amino-N-ethyl-acetamide
  参考文献：
  名称：

  JP5874871

  摘要：

  公开号：

文献信息

• [EN] SUBSTITUTED AMIDINE COMPOUNDS FOR COMBATING ANIMAL PESTS<br/>[FR] COMPOSÉS AMIDINE SUBSTITUÉS DESTINÉS À LUTTER CONTRE LES ANIMAUX NUISIBLES
  申请人：BASF SE

  公开号：WO2010072602A1

  公开（公告）日：2010-07-01

  The invention relates to substituted amidine compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to the use of the substituted amidine compounds, of their salts or of compositions comprising them for combating animal pests. Furthermore the invention relates also to methods of applying such substituted amidine compounds. The substituted amidine compounds of the present invention are defined by formula (I) wherein A1 to A4, B1 to B3, R1 to R3, (R4)p, (R5)q, X and Y are defined as in the description.

  该发明涉及式(I)的取代胺基化合物，其对映异构体、顺反异构体及其盐，以及包含这种化合物的组合物。该发明还涉及使用这些取代胺基化合物、它们的盐或包含它们的组合物来对抗动物害虫。此外，该发明还涉及应用这种取代胺基化合物的方法。本发明的取代胺基化合物由式(I)定义，其中A1至A4、B1至B3、R1至R3、(R4)p、(R5)q、X和Y的定义如描述中所述。
• TERTIARY AMINES, MEDICAMENTS CONTAINING SAID AMINES, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF
  申请人：HAMPRECHT Dieter

  公开号：US20130316981A1

  公开（公告）日：2013-11-28

  The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

  本发明涉及一般式(I)的化合物及其互变异构体和盐，特别是其与无机或有机酸和碱形成的药用盐，具有有价值的药理特性，尤其是对上皮钠通道的抑制作用，以及其在治疗疾病，特别是肺部和呼吸道疾病方面的用途。
• [EN] TERTIARY AMINES, MEDICAMENTS CONTAINING SAID AMINES, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF<br/>[FR] AMINES TERTIAIRES, MÉDICAMENTS CONTENANT LESDITES AMINES, LEUR UTILISATION ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013174757A1

  公开（公告）日：2013-11-28

  The present invention relates to compounds of general formula (I), and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

  本发明涉及一般式（I）的化合物，以及其互变异构体和盐，特别是其与无机或有机酸和碱形成的药用盐，具有有价值的药理特性，特别是对上皮钠通道具有抑制作用，用于治疗疾病，特别是肺部和呼吸道疾病。
• Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
  申请人：——

  公开号：US20040058912A1

  公开（公告）日：2004-03-25

  The invention relates to novel benzazepines and related heterocyclic derivatives (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.

  该发明涉及新型苯并吡嗪和相关杂环衍生物（I），以及它们作为药物组成物中的活性成分的用途。该发明还涉及相关方面，包括用于制备这些化合物的过程、含有这些化合物中的一个或多个的药物组成物，特别是它们作为促进睡眠的受体拮抗剂的用途。
• Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists
  作者：Susan E. Napier、Jeffrey J. Letourneau、Nasrin Ansari、Douglas S. Auld、James Baker、Stuart Best、Leigh Campbell-Wan、Jui-Hsiang Chan、Mark Craighead、Hema Desai、Katharine A. Goan、Koc-Kan Ho、Ellen G.J. Hulskotte、Cliona P. MacSweeney、Rachel Milne、J. Richard Morphy、Irina Neagu、Michael H.J. Ohlmeyer、Ard W.M.M. Peeters、Jeremy Presland、Chris Riviello、Ge S.F. Ruigt、Fiona J. Thomson、Heather A. Zanetakos、Jiuqiao Zhao、Maria L. Webb

  DOI：10.1016/j.bmcl.2010.12.081

  日期：2011.3

  Synthesis and structure–activity relationships (SAR) of a novel series of vasopressin V1b (V3) antagonists are described. 2-(4-Oxo-2-aryl-quinazolin-3(4H)-yl)acetamides have been identified with low nanomolar affinity for the V1b receptor and good selectivity with respect to related receptors V1a, V2 and oxytocin (OT). Optimised compound 12j demonstrates a good pharmacokinetic profile and activity

  合成和结构-活性关系（SAR）的一系列新的加压素V 1b（V 3）拮抗剂。已确定2-（4-氧代-2-芳基-喹唑啉-3（4 H）-基）乙酰胺对V 1b受体的纳摩尔亲和力低，并且对相关受体V 1a，V 2和催产素的选择性很好（ OT）。优化的化合物12j在HPA功能障碍的机械模型中显示出良好的药代动力学特征和活性。